Evidence map›Paper›PMID 34978889›Full record

ArticleAntimicrobial agents and chemotherapy2022

Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors

Masayuki Amano, Ravikiran S Yedidi, Pedro Miguel Salcedo-Gómez, Hironori Hayashi, Kazuya Hasegawa, Cuthbert D Martyr, Arun K Ghosh, Hiroaki Mitsuya

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Masayuki AmanoDepartment of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Hospitalgrid.411152.2, Kumamoto, Kumamoto, Japan.ORCID 0000-0003-0516-9502
Ravikiran S YedidiExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-2755-1307
Pedro Miguel Salcedo-GómezDepartment of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Hospitalgrid.411152.2, Kumamoto, Kumamoto, Japan.
Hironori HayashiDepartment of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Hospitalgrid.411152.2, Kumamoto, Kumamoto, Japan.
Kazuya HasegawaProtein Crystal Analysis Division, Japan Synchrotron Radiation Research Institutegrid.410592.b, Kouto, Japan.
Cuthbert D MartyrDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Arun K GhoshDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Hiroaki MitsuyaDepartment of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Hospitalgrid.411152.2, Kumamoto, Kumamoto, Japan.ORCID 0000-0001-9274-3853
Kumamoto University Hospital · JPPurdue University West Lafayette · USAndhra University · INJapan Synchrotron Radiation Research Institute · JPNational Institutes of Health · USTohoku University · JP

Funding

Development of Antiviral Therapy of HIV-1 InfectionZIASC006738 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI MITSUYA, HIROAKI · 2009 to 2025
$10.0M
Design & Synthesis of Nonpeptide Protease InhibitorsR01AI150466 · NIAID · PURDUE UNIVERSITY · PI ARUN K GHOSH · 2023 to 2026
$2.4M
Design & Synthesis of Nonpeptide Protease InhibitorsR37AI150466 · NIAID · PURDUE UNIVERSITY · PI GHOSH, ARUN K · 2019 to 2020
$969k
NIAID NIH HHS R01 AI150466NIAID NIH HHS R37 AI150466
6 · The paper itself

Abstract

To date, there are no specific treatment regimens for HIV-1-related central nervous system (CNS) complications, such as HIV-1-associated neurocognitive disorders (HAND). Here, we report that two newly generated CNS-targeting HIV-1 protease (PR) inhibitors (PIs), GRL-08513 and GRL-08613, which have a P1-3,5-

Indexed as

HIV-1HIV Protease InhibitorsBlood-Brain BarrierCentral Nervous SystemFluorineHIV ProteaseHumansVirus ReplicationFluorineHIV ProteaseHIV Protease Inhibitorsp16 protease, Human immunodeficiency virus 1blood-brain barriercentral nervous system infectionsHIV-1HIV-1-associated neurocognitive disordersprotease inhibitors

Identifiers

PMID34978889
PMCPMC8846478
OpenAlexW4205906424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.